Efficacy of Ciprofloxacin and Moxifloxacin against Nocardia brasiliensis In Vitro and in an Experimental Model of Actinomycetoma in BALB/c Mice

Efficacy of Ciprofloxacin and Moxifloxacin against Nocardia brasiliensis In Vitro and in an Experimental Model of Actinomycetoma in BALB/c Mice In Vivo Therapeutic Effect of Gatifloxacin on BALB/c Mice Infected with Nocardia brasiliensis In Vitro Activities of Tigecycline and Eight Other Antimicrobials against Different Nocardia Species Identified by Molecular Methods In Vivo Efficacy of Moxifloxacin Compared with Cloxacillin and Vancomycin in a Staphylococcus aureus Rabbit Arthritis Experimental Model In Vitro Activity of ACH-702, a New Isothiazoloquinolone, against Nocardia brasiliensis Compared with Econazole and the Carbapenems Imipenem and Meropenem Alone or in Combination with Clavulanic Acid Rapid Eradication of Listeria monocytogenes by Moxifloxacin in a Murine Model of Central Nervous System Listeriosis Brasiliquinones A, B and C, New Benz(a)anthraquinone Antibiotics from Nocardia brasiliensis. I. Producing Strain, Isolation and Biological Activities of the Antibiotics. Nocarasins A−C and Brasiliquinone D, New Metabolites from the Actinomycete <i>Nocardia</i> <i>brasiliensis</i> Brasilicardin A, a New Terpenoid Antibiotic from Pathogenic Nocardia brasiliensis: Fermentation, Isolation and Biological Activity. Orally Administered Combined Regimens for Treatment of Mycobacterium ulcerans Infection in Mice